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i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 2 1 9e2 2 8 221(2.15  0.27 mm vs. 2.25  0.24 mm; p ¼ 0.003). The majority
(89%) of lesions involved vessels with a diameter<2.5 mm.
Bailout stenting was required in 20% of lesions in the DEB
group. The primary endpoint of in-stent (in-balloon) late loss
was significantly less with DEB compared with PES
(0.08  0.38 mm vs. 0.29  0.44 mm; difference 0.21; 95% CI:
0.34 to 0.09; p noninferiority < 0.001; p superiority ¼ 0.001).
At 6 months, DEB and PES were associated with similar rates
of angiographic restenosis (8.9% vs. 14.1%; p ¼ 0.25), target
lesion revascularization (4.4% vs. 7.6%; p ¼ 0.37), and MACE
(7.8% vs. 13.2%; p ¼ 0.77).
Conclusions: Treatment of small-vessel disease with a
paclitaxel DEB was associated with less angiographic late loss
and similar rates of restenosis and revascularization as a PES.
1. Perspective
Themain findings of the BELLO trial are: in patientswith small
vessel CAD, the IN.PACT Falcon paclitaxel-coated DEB is non-
inferior to PES (Taxus Liberte) in suppressing neointimal
proliferation as measured by angiographic late loss at 6
months. Also the rates of MACE, MI and TLR were similar
between the two groups. However, these results were
obtained with the need to implant BMS in 20% of patients
randomized to DEB. Though the validity of late loss as a pri-
mary endpoint may be questioned; two recent trials (one in
patients with ISR and the other in AMI patients) had used this
as an endpoint. Despite the suboptimal acute angiographic
result as measured by final MLD and acute gain, DEB was
associated with similar end-points at 6 months as PES. This is
probably explained by the fact that the lower acute gain with
DEBwas counterbalanced by the very low late loss resulting in
a net lumen gain, which was comparable in both groups.
DEB can provide a therapeutic option in very small vessels
(<2.25 mm), which comprised more than half of the lesions
treated in this study, for which DES sizes are not available.
Till the results of the BELLO trial were out, limited data
was available regarding DEB in de-novo small-vessel disease.
The only other published study, PICCOLETO was a small
single-center trial that randomized 60 patients with small-
vessel disease (2.75 mm) to the Dior paclitaxel-coated bal-
loon or PES. This trial was stopped prematurely because of
the clear superiority of PES both in terms of angiographic
restenosis and MACE. Although the Dior and IN.PACT Falcon
DEB are both coated with paclitaxel at 3 mg/mm2, these
technologies are not comparable and differ significantly in
regards to balloon technology, drug-coating process, exci-
pient used as drug carrier and transport facilitator to the
vessel wall. As has been demonstrated with DES platforms,
clinical outcomes may be very different, despite elution of
the same drug. The only other DEB data available on small
vessel disease is the PEPCAD-I SVD study. In this pro-
spective, nonrandomized multicentre study, 122 patients
with CAD in 2.25e2.8 mm diameter vessels were treated with
SeQuent Please paclitaxel-coated DEB. This study demon-
strated a higher late loss in lesions treated with a combi-
nation of DEB and BMS, especially if geographic mismatch
occurred (i.e., stent implanted in an area that was not trea-
ted with DEB). In the BELLO study, this geographic mismatch
has been carefully avoided, which might explain the lowerlate loss rates even when a BMS was needed to be used. The
lower late loss in patients treated only with DEB in the
present study can also be explained by the fact that less
complex lesions were selected, where the possibility of
requirement of additional stenting was low. It is also
important to note that patients treated with DEB alone did
not experience any thrombotic event, acute vessel closure or
higher rate of periprocedural MI.
In my opinion, after the results of BELLO trial, DEB can be
used as an adjunctive tool but not as a substitute to DES. In
addition to its proven role in in-stent restenosis, DEB can be
used in circumstances in which the operator may not be fully
confident to deploy a DES such as in the treatment of lesions
in very small vessels (<2.25mmdiameter) as DES is available
only upto 2.25 mm. Till now we do not have any treatment
strategy for such vessels which can be an important diagonal,
obtuse marginal, PDA or PLV branches. Also it can be thought
of as a strategy in very long lesions to avoid the excessive
number of DES that may be required. However, till such time
that larger studies with hard clinical end-points become
available, it would not be wise to use DEB in lesions of
2.5 mm diameter as DES are available for these sizes and
with newer generation DES available, the restenosis rates and
MACE are also much lower.
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Background: To assess the proportion and long-term
outcomes of patients with idiopathic dilated cardiomyop-
athy and potential indications for implantable cardioverter-
defibrillator before and after optimization of medical
treatment, 503 consecutive patients with idiopathic dilated
cardiomyopathy were evaluated from 1988 to 2006.
Results: A total of 245 patients (49%) satisfied the
“Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
criteria,” defined as a left ventricular ejection fraction of
<0.35 and New York Heart Association (NYHA) class IIeIII
on registration. Among these, 162 (group A) were re-
evaluated 5.4  2 months later with concurrent beta
blockers and angiotensin-converting enzyme inhibitor use.
Of the 162 patients, 50 (31%) still had “SCD-HeFT criteria”
(group A1), 109 (67%) had an improved left ventricular
ejection fraction and/or New York Heart Association class
(group A2), and 3 (2%) were in NYHA class IV. Of the 227
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 2 1 9e2 2 8222patients without baseline “SCD-HeFT criteria” (left ven-
tricular ejection fraction >0.35 or NYHA class I), 125 were
evaluated after 5.5  2 months. Of these 227 patients, 13
(10%) developed “SCD-HeFT criteria” (group B1), 111 (89%)
remained without “SCD-HeFT criteria” (group B2), and 1
(1%) had worsened to NYHA class IV. The 10-year mortal-
ity/heart transplantation and sudden death/sustained
ventricular arrhythmia rate was 57% and 37% in group A1,
23% and 20% in group A2 (p < 0.001 for mortality/heart
transplantation and p e 0.014 for sudden death/sustained
ventricular arrhythmia vs. group A1), 45% and 41% in group
B1 ( p e NS vs. group A1), 16% and 14% in group B2 ( p e NS
vs. group A2), respectively.
Conclusion: Two thirds of patients with idiopathic
dilated cardiomyopathy and “SCD-HeFT criteria” at pre-
sentation did not maintain implantable cardioverter-
defibrillator indications 3e9 months later with optimal
medical therapy. Their long-term outcome was excellent,
similar to that observed for patients who had never met the
“SCD-HeFT criteria.”
1. Perspective
Since the publication of the SCD-HeFT and the DEFINITE
trials, treatment with ICD for the primary prevention of
sudden cardiac death (SCD) has been extended to patients
with idiopathic dilated cardiomyopathy (IDC), who have a
LVEF of 0.35 and who are classified as NYHA II or III (“SCD-
HeFT criteria,” class I B indication). The appropriate timing
for ICD implantation, however, is still uncertain. Current
guidelines suggest that an ICD should be considered in
addition to medical therapy, but many patients are treated
with an ICD without evidence-based indications, mainly
because of newly diagnosed heart failure and before treat-
ment optimization. This study evaluated the proportion of
patients with and without potential indications for ICD
implantation at presentation and the long-term prognosis of
patients with initial ICD indications but who improved after
optimization of medical treatment. It also compared the
long-term outcome of “improved” patients to those main-
taining “SCD-HeFT criteria” and those who never met “SCD-
HeFT criteria.”
This trial included only patients who were not on beta
blockers. After initial assessment, optimization of medical
treatment was achieved with gradually up-titrating doses of
beta blockers and ACEI/ARB at the highest tolerated dose over
a period of 3e9 months.
The main results of the present study are: 1) 50% patients
had SCD-HeFT criteria at first assessment and would have
otherwise received an ICD. 2) 2/3rd of patients with SCD-HeFT
criteria at baseline “improved” and no longermaintained SCD-
HeFT criteria 5.5 months after starting beta blocker and ACEI
treatment. 3) The long-term SCD were similar in “improved”
patients and in those without SCD-HeFT criteria, suggesting
ICD implantation should not be done in most patients with
low LVEF and HF symptoms before optimization of medical
treatment. 4) SCD (4 patients e 2%) was similar in patients
both with and without SCD-HeFT criteria before second
evaluation at 3e9 months, confirming the difficulty of strat-
ifying risk of SCD at first evaluation.This study emphasizes how important is the optimization
of medical therapy in patients initially presenting with ICD
indications and ICD implantation can be avoided in the
majority of such patients. Even in USA, nearly 22.5% of
patients with an ICD did not meet the evidence-based cri-
teria for implantation, mainly because of newly diagnosed
HF (62%). Such unnecessary ICD implantations should be
avoided because of economic issues (especially in a devel-
oping country like India), the risk of complications asso-
ciated with implantation and inappropriate shocks (inw25%
of patients).
What then is the waiting period for ICD implantation after
onset of HF symptoms in patients with LVEF 35%? Well, we
have no clear-cut answer. Data from DEFINITE trial suggest
early ICD implantation (<9months or even<3months) ismore
beneficial while the Cardiomyopathy Trial showed otherwise.
One position could be that at least 3 months are required
for up-titration of doses of beta blockers and ACEI while
waiting for >9 months could well be unnecessary and poten-
tially harmful. So a mean waiting period of 6 months could be
advocated during which we should try and maintain opti-
mally tolerated doses of beta blockers and ACEI/ARB. At 6
months of follow-up, re-assessment of LVEF using Echo-
cardiography/MUGA scan, Holter monitoring to rule out
NSVT, EPS study to rule out inducible VF/sustained VT not
suppressible by a class I antiarrhythmic drug should be done
and patients should be very carefully selected for ICD.
However, a word of caution is that this trial only included
patients with idiopathic dilated cardiomyopathy and the
results cannot be extrapolated to ischemic cardiomyopathy.
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E-mail address: khanal.s@rediffmail.comEvolve trialChronic Kidney Disease (CKD) is now considered a risk
factor for coronary artery disease. Secondary hyper-para-
thyroidism, a disorder of mineral metabolism in patients of
CKD contributes to extra skeletal calcification including car-
diovascular system which is partial responsible for increased
risk of cardiovascular disease.1
It will not be inappropriate to call parathormone as uremic
toxin and level above 600 mg/ml increases the risk of death and
cardiovascular reasons. Cinacalcet is a calcimimetic agent
which acts by allosteric activation of calcium sensing recep-
tors on Parathyroid tissues. This was approved for hyper-
parathyroidism secondary to Chronic Renal Failure (CRF) after
the effect on reducing parathormone specially in patients on
dialysis was shown in multiple randomized trials.2
In EVOLVE Trial (Effect of Cinacalcet on Cardiovascular
Disease in Patients undergoing Dialysis), N Engl J Med.
2012;367:2482e2494, this hypothesis was tested by using
Cinacalcet in addition to conventional therapy for CKD
